Based on these results, FDA approved pembrolizumab for the treatment of patients with PD-L1-positive recurrent or advanced-stage GC/GEC, who have received two or more lines of chemotherapy, including fluoropyrimidine- and platinum-based chemotherapy, and HER2-neu-targeted therapy in eligible patients. Here, ERBB2 is linked to gastric cancer.